Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo vitamin settlement

This article was originally published in The Tan Sheet

Executive Summary

Private labeler will record $20.1 mil. pre-tax gain in fiscal fourth quarter ending June 30 stemming from settlements in vitamin price-fixing litigation. Settlement proceeds, which were received May 17, will boost net income by approximately $12.9 mil. Perrigo recorded $7.8 mil. pre-tax gain in Q3 following similar settlements (1"The Tan Sheet" Feb. 18, 2002, p. 14)...

You may also be interested in...

Perrigo vitamin settlement

Private labeler will record $7.8 mil. pre-tax gain in third quarter ending March 31 stemming from settlement with unidentified defendants in vitamin price-fixing litigation. "Effect on net income will be approximately $5 mil.," firm says in Feb. 1 SEC filing. Case against remaining price-fixing defendants is proceeding, notes Allegan, Mich.-based firm, which previously reported vitamin litigation settlement payments of $995,000 and $4.2 mil. for FY 2001 and 2000, respectively...

US Election 2020: Device Firms Spending Twice As Much On Biden Than On Trump

Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.

Orphazyme Raises Funds, Approaching Markets With Novel Niemann-Pick Therapy

Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts